Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 977  

    Article Cited by others


Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study

Aghdam Ramin Akbarian, Amoui Mahasti, Ghodsirad Mohammadali, Khoshbakht Sepide, Mofid Bahram, Kaghazchi Fateme, Tavakoli Mehrdad, Pirayesh Elahe, Ahmadzadehfar Hojjat

Year : 2019| Volume: 18| Issue : 3 | Page no: 258-265

   This article has been cited by
1 A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
Srikanth Boinapally,Hye-Hyun Ahn,Bei Cheng,Mary Brummet,Hwanhee Nam,Kathleen L. Gabrielson,Sangeeta R. Banerjee,Il Minn,Martin G. Pomper
Scientific Reports. 2021; 11(1)
[Pubmed]  [Google Scholar] [DOI]
2 The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer
Dominic Bagguley,Sean Ong,James P Buteau,Sam Koschel,Nattakorn Dhiantravan,Michael S Hofman,Louise Emmett,Declan G Murphy,Nathan Lawrentschuk
Future Oncology. 2021;
[Pubmed]  [Google Scholar] [DOI]
3 Theranostic approaches in nuclear medicine: current status and future prospects
Luca Filippi,Agostino Chiaravalloti,Orazio Schillaci,Roberto Cianni,Oreste Bagni
Expert Review of Medical Devices. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
4 Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
Finn Edler von Eyben,Glenn Bauman,Rie von Eyben,Kambiz Rahbar,Cigdem Soydal,Alexander R. Haug,Irene Virgolini,Harshad Kulkarni,Richard Baum,Giovanni Paganelli
International Journal of Molecular Sciences. 2020; 21(23): 9054
[Pubmed]  [Google Scholar] [DOI]
5 Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
Hojjat Ahmadzadehfar,Kambiz Rahbar,Richard P. Baum,Robert Seifert,Katharina Kessel,Martin Bögemann,Harshad R Kulkarni,Jingjing Zhang,Carolin Gerke,Rolf Fimmers,Clemens Kratochwil,Hendrik Rathke,Harun Ilhan,Johanna Maffey-Steffan,Mike Sathekge,Levent Kabasakal,Francisco Osvaldo Garcia-Perez,Kalevi Kairemo,Masha Maharaj,Diana Paez,Irene Virgolini
European Journal of Nuclear Medicine and Molecular Imaging. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Neutron-activated theranostic radionuclides for nuclear medicine
Hun Yee Tan,Chai Hong Yeong,Yin How Wong,Molly McKenzie,Azahari Kasbollah,Mohamad Nazri Md. Shah,Alan Christopher Perkins
Nuclear Medicine and Biology. 2020;
[Pubmed]  [Google Scholar] [DOI]
7 A walk with Lu-177 PSMA: How close we have reached from bench to bedside?
Manoj Gupta,G. Karthikeyan,P. S. Choudhury,Venkata Pradeep Babu,Manish Sharma,Parveen Jain,Ineet Talwar,Amitabh Singh,Sudhir Rawal
Cancer Investigation. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
8 Precision Medicine Approach in Prostate Cancer
Majid Assadi,Narges Jokar,Mojtaba Ghasemi,Iraj Nabipour,Ali Gholamrezanezhad,Hojjat Ahmadzadehfar
Current Pharmaceutical Design. 2020; 26(31): 3783
[Pubmed]  [Google Scholar] [DOI]
9 Bench-to-Bedside Theranostics in Nuclear Medicine
Narges Jokar,Majid Assadi,Anna Yordanova,Hojjat Ahmadzadehfar
Current Pharmaceutical Design. 2020; 26(31): 3804
[Pubmed]  [Google Scholar] [DOI]
10 Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Michael Sun,Muhammad O Niaz,Adlai Nelson,Myrto Skafida,Muhammad J Niaz
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
11 Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer
Nasim Vahidfar,Maryam Fallahpoor,Saeed Farzanehfar,Ghasemali Divband,Hojjat Ahmadzadehfar
Journal of Radioanalytical and Nuclear Chemistry. 2019;
[Pubmed]  [Google Scholar] [DOI]


Read this article